CU Cancer Center member Christopher Lieu, MD, and Namrata Vijayvergia, MD, of the Fox Chase Cancer Center conclude their discussion with considerations for managing immunotherapy-related toxicities in patients with metastatic hepatocellular carcinoma (HCC), along with a review of the available evidence regarding the duration of immunotherapy treatment.